Ibudilast

Amyotrophic Lateral Sclerosis

MediciNovaSmall moleculePhase 2/3Active

BB

64/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 59/ 100
Competitive Position: 73/ 100

Competitive context

150 Active assets in the Amyotrophic Lateral Sclerosis cohort.

Asset / Sponsor	Phase	Rating
TAURURSODIOL Amylyx Pharmaceuticals Inc.	Phase 3	BBB
Tofersen Biogen	Phase 4	BBB
Riluzole AB Science	Phase 4	BB
Mexiletine Bjorn Oskarsson, MD	Phase 4	BB
DIACETYL(N(4)-METHYLTHIOSEMICARBAZONATO) COPPER (II) Collaborative Medicinal Development Pty Limited	Phase 2/3	BB

View all 50 →

Same molecule, other indications

Ibudilast is also rated in:

primary progressive multiple sclerosisDormant

B

Indicative ·

57 / 100

secondary progressive multiple sclerosisDormant

B

Indicative ·

57 / 100

diabetic neuropathyDormant

CCC

Indicative ·

52 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.